High diagnostic concordance between vulvar and cervical samples for human papillomavirus detection: a cross-sectional study
Open Access
- 1 September 2026
- journal article
- research article
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (9)
Abstract
Low compliance with clinician-collected cervical sampling and implementation barriers in resource-limited settings limit human papillomavirus (HPV)-based cervical cancer prevention. Vulvar sampling is non-invasive and easier to perform, but its agreement with cervical HPV testing remains insufficiently defined. We retrospectively analyzed 719 paired vulvar and cervical specimens tested by clinically validated fluorescence PCR to evaluate concordance between sampling sites and the potential utility of vulvar HPV testing. High-risk HPV (hrHPV) positivity was 47.98% (345/719) in vulvar samples and 43.53% (313/719) in cervical samples, with strong site-to-site concordance (κ = 0.821). The negative predictive value of vulvar hrHPV testing for concurrent cervical hrHPV positivity was 95.72%. Concordance was highest for HPV18 (κ = 0.892; negative predictive value [NPV] = 99.41%), followed by HPV16 (κ = 0.839), and low-risk HPV6/11 (κ = 0.746). Among five biopsy-confirmed cervical intraepithelial neoplasia cases, vulvar and cervical HPV results were fully concordant. Age-stratified analysis showed peak hrHPV infection in women younger than 30 years. In women aged 40–49 years, vulvar hrHPV positivity exceeded cervical positivity (56.52% vs 45.65%). Agreement was lower among women aged ≥40 years for hrHPV and lrHPV testing. Among discordant cases, 93.75% (15/16) of vulvar-negative/cervical-positive cases had prior HPV-related treatment, whereas non-HPV16/18 types predominated in vulvar-positive/cervical-negative cases (91.67%, 44/48). Vulvar HPV testing showed high concordance with paired cervical testing and may help identify women at low likelihood of concurrent cervical hrHPV positivity. These findings support prospective evaluation of vulvar sampling as a non-invasive adjunct for HPV testing, particularly for women with low acceptance of cervical sampling or limited access to conventional screening. IMPORTANCE: Conventional cervical human papillomavirus (HPV) screening remains inaccessible to some women because of discomfort, perceived invasiveness, privacy concerns, and implementation barriers. This study shows that HPV testing with vulvar swabs, a truly non-invasive sampling site, has high concordance with paired cervical testing (κ = 0.821). The high negative predictive value of vulvar high-risk HPV (hrHPV) testing for concurrent cervical hrHPV negativity (95.72%) suggests that a negative vulvar result may identify women at low likelihood of cervical hrHPV positivity, potentially reducing unnecessary referrals. These findings are relevant for older and postmenopausal women, in whom cervical atrophy may decrease the sensitivity of HPV detection. Overall, our results provide preliminary support for prospective evaluation of vulvar sampling as a patient-friendly adjunct to HPV testing, particularly for women with low acceptance of cervical sampling or limited access to conventional screening. Population-based validation with cytological and histological endpoints is required before broader implementation.Keywords
Funding Information
- National Natural Science Foundation of China (82203346)
- the New Technology Development Fund of Nanjing Drum Tower Hospital (XJSFZJJ202017, XJSFZLX202435)
This publication has 25 references indexed in Scilit:
- Human papillomaviruses: diversity, infection and host interactionsNature Reviews Microbiology, 2021
- Better cancer screening in resource-poor nationsNature, 2020
- Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic reviewEuropean Journal of Cancer, 2020
- Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countriesThe Lancet, 2020
- Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysisThe Lancet Global Health, 2020
- Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysisThe Lancet Oncology, 2014
- High‐risk HPV testing on self‐sampled versus clinician‐collected specimens: A review on the clinical accuracy and impact on population attendance in cervical cancer screeningInternational Journal of Cancer, 2012
- Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: A pooled analysis of 17 population‐based studiesInternational Journal of Cancer, 2012
- Liposome fusogenicity and entrapment efficiency of antigen determine the Th1/Th2 bias of antigen-specific immune responseVaccine, 2009
- Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenanNature Medicine, 2007